Impax Laboratories — 35th Annual J.P. Morgan Healthcare Conference (January 2017)
17 slides from Impax Laboratories's conference presentation, Jan 11, 2017

Slide 1: 35th Annual J.P. Morgan Healthcare Conference
1 35th Annual J.P. Morgan Healthcare Conference January 11, 2017

Slide 2: Cautionary Statement Regarding Forward Looking Statements
2 Impax Cautionary Statement Regarding Forward Looking Statements "Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this news release contain information that is not historical; these statements are forward-looking in nature and

Slide 3: Impax at a Glance
3 Impax at a Glance Generic Division Targeting high-value solid oral and alternative dosage form ANDAs that are difficult to develop • Diversified commercial portfolio of ~72 products • 25 ANDAs pending approval at FDA • 26 ANDAs under development Specialty Pharma Division Focused on developing bran

Slide 4: Leveraging Our Strengths and Focusing on Opportunities for Growth
4 Leveraging Our Strengths and Focusing on Opportunities for Growth • Select the right products for internal and partnership development • Continue focus on sustainable quality and compliance programs • Develop, file and launch on time and capitalize on market disruptions • Ensure effective and comp

Slide 5: Aligning Organization and Resources to Support Growth Initiatives
5 Aligning Organization and Resources to Support Growth Initiatives Completed/In-Process Estimated Annual Savings ~$41MM-$47MM* Operational and R&D restructuring (2015) Closed central packaging operation/transferred distribution to UPS (2015) Closing Middlesex, NJ manufacturing and packaging facilit

Slide 6: Diversified Generic Portfolio of Solid Oral and Alternative Dose Form Products
6 Diversified Generic Portfolio of Solid Oral and Alternative Dose Form Products 13 50 9 Commercialized Portfolio of 72 Products Controlled Release SOD Other SOD Alternative Dose SOD – Solid Oral Dose; Data as of Dec. 31, 2016 Product Portfolio by Number of Competing Generic Products Sole player in

Slide 7: Growing Epinephrine Auto-Injector
7 Growing Epinephrine Auto-Injector 0% 1% 2% 3% 4% 5% 6% 7% 8% 9% 10% 2 0 1 6 /0 1 /0 1 2 0 1 6 /0 1 /0 8 2 0 1 6 /0 1 /1 5 2 0 1 6 /0 1 /2 2 2 0 1 6 /0 1 /2 9 2 0 1 6 /0 2 /0 5 2 0 1 6 /0 2 /1 2 2 0 1 6 /0 2 /1 9 2 0 1 6 /0 2 /2 6 2 0 1 6 /0 3 /0 4 2 0 1 6 /0 3 /1 1 2 0 1 6 /0 3 /1 8 2 0 1 6 /0 3 /

Slide 8: Continuing to Expand Generic Pipeline
8 Continuing to Expand Generic Pipeline Source of sales data: IMS NPA Nov. 2016; *U.S. Brand/Generic market sales; Pipeline data as of Dec. 31, 2016 Portfolio of 51 Products Targeting Current U.S. Brand/Generic Market of $24B Solid Oral Dose Products Alternative Dose Products Total Products Potentia

Slide 9: ANDA Pipeline Includes Several Potential High-Value First-to-Market Opportunities
9 ANDA Pipeline Includes Several Potential High-Value First-to-Market Opportunities Source of sales data: IMS NPA Nov. 2016; Pipeline data as of Dec. 31, 2016; TA = tentative approval 1 Launched authorized generic in April 2016 2 Assuming final FDA approval, earliest potential launch date/timing bas

Slide 10: Specialty Pharma Portfolio
10 Product Therapeutic Area Parkinson’s Disease Migraine Anthelmintic Anthelmintic Specialty Pharma Portfolio

Slide 11: Actions Taken to Deliver Growth
11 Actions Taken to Deliver Growth 0.0% 1.0% 2.0% 3.0% 0 2,000 4,000 6,000 8,000 10,000 12,000 14,000 CD L D S h a re T R x Monthly TRx and Share of National CD-LD TRx Since Launch Rytary TRx CD-LD Share • Redefined clinical messaging related to formulation • Simplified dose conversion guidance for

Slide 12: Patient Support Program Introduced
12 Patient Support Program Introduced • Third-party managed • Patient specific case manager • Prior authorization status updates • Appeals support • Commercial copay assistance support • Trial product vouchers • Alternative funding referrals • Patient assistance program application support • Educati

Slide 13: Specialty Pharma R&D: IPX203
13 Specialty Pharma R&D: IPX203 Investigator Assessment of Motor State Off Time (h) On Time (h) Immediate-release CD-LD 7.3 2.7 Rytary 5.5* 4.4* IPX203 4.6 * + 5.4 * + * p ≤ 0.0002 compared to IR CD-LD + p < 0.05 compared with Rytary Improvement from Baseline in MDS-UPDRS Part III • Enrolling patien

Slide 14: Positive Performance Trend
14 Positive Performance Trend 0% 10% 20% 30% 40% 50% 2,000 4,000 6,000 8,000 10,000 12,000 14,000 A pr -1 2 J u n -1 2 A u g -1 2 O c t- 1 2 D e c -1 2 F e b -1 3 A pr -1 3 J u n -1 3 A u g -1 3 O c t- 1 3 D e c -1 3 F e b -1 4 A pr -1 4 J u n -1 4 A u g -1 4 O c t- 1 4 D e c -1 4 F e b -1 5 A pr -1

Slide 15: Building Awareness of Anthelmintic Franchise
15 Building Awareness of Anthelmintic Franchise 0% 10% 20% 30% 40% 50% 0 500 1,000 1,500 2,000 2,500 3,000 3,500 4,000 3 /2 5 4 /1 4 /8 4 /1 5 4 /2 2 4 /2 9 5 /6 5 /1 3 5 /2 0 5 /2 7 6 /3 6 /1 0 6 /1 7 6 /2 4 7 /1 7 /8 7 /1 5 7 /2 2 7 /2 9 8 /5 8 /1 2 8 /1 9 8 /2 6 9 /2 9 /9 9 /1 6 9 /2 3 9 /3 0 1 0

Slide 16: Current Priorities
16 Current Priorities Focus on quality and operations Maximize profitability within generic portfolio Effectively execute on Rytary® and Emverm® growth initiatives Capitalize on new generic product launches Continue to build diversification within our portfolio Explore additional expense savings and

Slide 17: Investment Thesis
17 Investment Thesis Pipeline data as of Dec. 31, 2016 Source of sales data: IMS Nov. 2016; *U.S. Brand/Generic market sales; • Generic pipeline of 51 products targeting $24B U.S. sales* • Specialty pipeline focused on next generation opportunities • Solid platform on which to build long-term growth
Source: SEC EDGAR · 8-K filed Jan 11, 2017
More decks from Impax Laboratories Inc
Q4 2017 Earnings Presentation23 slides · Mar 1, 2018
J.P. Morgan Global Healthcare Conference 201819 slides · Jan 9, 2018
Q3 2017 Earnings Presentation22 slides · Nov 9, 2017
Merger or Acquisition (October 2017)22 slides · Oct 17, 2017
Merger or Acquisition (October 2017)43 slides · Oct 17, 2017
Q2 2017 Earnings Presentation24 slides · Aug 9, 2017